An FDA alert warned of problems with some Mobile Power Units of the HeartMate II and HeartMate 3 left ventricular assist devices. Medtronic's thin OmniaSecure defibrillation lead got FDA approval for ...

Atrial fibrillation (AFib) is a type of irregular heartbeat. Longstanding persistent AFib lasts for 12 months or more, while permanent AFib is when a person and their doctor decide to no longer ...

The FDA approved the first pulsed field ablation (PFA) catheter, the PulseSelect PFA system, for the treatment of paroxysmal and persistent atrial fibrillation (Afib), Medtronic announced on Wednesday ...

PFA is associated with a significantly lower risk for recurrence of atrial arrhythmia compared with antiarrhythmic-drug therapy receipt.

AVANT GUARD trial meets expectations despite pause for safety modifications ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Previously, patients with advanced atrial fibrillation (AF ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Tailored ablation guided by AI better prevented atrial ...

We conducted an international, randomized trial involving patients with previously untreated persistent atrial fibrillation. The patients were randomly assigned in a 2:1 ratio to receive PFA performed ...

Atrial fibrillation (AF), the most common chronic cardiac arrhythmia in clinical practice, is very challenging to treat once it becomes persistent, after which spontaneous return to normal rhythm ...

Guidelines for the management of atrial fibrillation in different parts of the world are largely in agreement on how to handle the condition, but differences can help shed light on alternate ...

The AVANT GUARD trial found that first-line pulsed field ablation (PFA) reduced atrial arrhythmia recurrence more than antiarrhythmic drugs in persistent atrial fibrillation. At 12 months, 56% of PFA ...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced U.S. Food and ...